In a report released yesterday, Alex Thompson CFA from Stifel Nicolaus reiterated a Buy rating on Spyre Therapeutics (SYRE – Research Report).

In a report released yesterday, Stephen Willey from Stifel Nicolaus maintained a Buy rating on X4 Pharmaceuticals (XFOR – Research Report). The ...

D-Wave Quantum (NYSE:QBTS) said in a regulatory filing on Friday that it entered a sales agreement with agents, under which ...

Stifel Nicolaus reaffirmed their hold rating on shares of Accolade (NASDAQ:ACCD – Free Report) in a research note published ...

Jack in the Box (NASDAQ:JACK – Get Free Report) had its price objective reduced by research analysts at Stifel Nicolaus from ...

Discover three oversold biotech/biopharma stocks to watch amidst market volatility and the JP Morgan Healthcare event in San ...

We recently published a list of Top 10 AI Stocks on Wall Street’s Radar. In this article, we are going to take a look at ...

Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by ...

The financial services giant is expanding its investment banking business by snapping up a specialist firm catering to the ...

Stifel’s broker-dealer clients are served in the United States through Stifel, Nicolaus & Company, Incorporated, including its Eaton Partners and Miller Buckfire business divisions; Keefe ...

A debt-free choice is Stifel, based in St. Louis, Missouri. It’s a brokerage firm (Stifel Nicolaus) and investment management company that has grown rapidly through acquisitions. Financial firms ...

Stifel Financial Cor this week announced that Schluckebier Hood Wealth Management Group of its Stifel, Nicolaus & Company, Incorporated broker-dealer subsidiary has been named to Forbes’ 2025 ...